DelveInsight Business Research LLP

Albany, NY -- (SBWire) -- 07/05/2019 --Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2028

7 July 2019

1. Prurigo Nodularis prevalent rate is increasing at 0.50% during the study period, i.e. 2016-2027
2. The higher Prurigo Nodularis diagnosed prevalence will be nearly 170,000 cases by the end of 2027 in the United States.
3. Japan accounts for the second highest diagnosed Prurigo Nodularis prevalence among the 7MM countries, with over 100,000 cases estimated to be reported by 2027

(Albany, US) DelveInsight launched a new report on Prurigo Nodularis Market Insights, Epidemiology and Market Forecast-2027

Key benefits

1. Prurigo Nodularis market report covers a descriptive overview and comprehensive insight of the Prurigo Nodularis epidemiology and Prurigo Nodularis market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Prurigo Nodularis market report provides insights on the current and emerging therapies.
3. Prurigo Nodularis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Prurigo Nodularis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Prurigo Nodularis market.
Request for sample pages

"Prurigo Nodularis Therapeutic market in the seven major markets (7MM) is expected to increase by 2027 at a CAGR of 4.32 % for the forecast period- 2016-2027."

The United States had the highest Prurigo Nodularis market size in 2016, which accounted for approximately 39% of the total 7 major markets. On the contrary, Spain accounted for the least market share (nearly 6%) among the 7MM countries.
Prurigo Nodularis Treatment is challenging. The current Prurigo Nodularis market can be classified, based on the severity of the disease, as mild, moderate and severe. There is a multimodal Prurigo Nodularis treatment algorithm consisting of topical and systemic therapies, where topical therapies are used for treating the visible form of the disease whereas the systemic therapies are used for symptomatic treatment. The symptomatic therapy aims to reduce itching and complete healing of lesions.
The off-label therapies, prescribed for Prurigo Nodularis treatment in the 7MM. Topical Corticosteroids contribute majorly to Prurigo Nodularis market size, with 55% in 2016, followed by the number of prescriptions for Topical Immunosuppresants/ Topical calcineurin inhibitors.

Key players such as
1. Menlo Therapeutics
2. Galderma R&D
3. Trevi Therapeutics
4. Kiniksa Pharmaceuticals
And many others

Companies are developing therapies for Prurigo Nodularis treatment like
1. Serlopitant
2. Nalbuphine ER
3. Nemolizumab
And many others

Table of contents

Report Introduction
2. Prurigo Nodularis Market Overview at a Glance
3. Prurigo Nodularis Disease Background and Overview
4. European Guideline on Prurigo Nodularis
5. FDA recommendations for Prurigo Nodularis treatment
6. Prurigo Nodularis Epidemiology and Patient Population
7. Prurigo Nodularis Country Wise-Epidemiology
7.1. United States- Epidemiology (2016-2027)
7.2. EU-5 - Epidemiology (2016-2027)
7.3. Germany-Epidemiology (2016-2027)
7.4. France-Epidemiology (2016-2027)
7.5. Italy-Epidemiology (2016-2027)
7.6. Spain-Epidemiology (2016-2027)
7.7. United Kingdom-Epidemiology (2016-2027)
7.8. Japan-Epidemiology (2016-2027)
8. Prurigo Nodularis Treatment Algorithm, Current Treatment, and Medical Practices
9. Prurigo Nodularis Unmet Needs
10. Prurigo Nodularis Emerging Therapies
10.1. Key Cross Competition
10.2. Serlopitant: Menlo Therapeutics
10.3. Nalbuphine ER: Trevi Therapeutics
10.4. Nemolizumab: Galderma
10.5. Apremilast: Celgene
10.6. M 118103: Maruho
11. Prurigo Nodularis Market Size
12. 7MM: Country-Wise Market Analysis
12.1. United States Market Size
12.2. Germany Market Size
12.3. France Market Size
12.4. Italy Market Size
12.5. Spain Market Size
12.6. United Kingdom Market Size
12.7. Japan Market Size
13. Market Drivers
14. Market Barriers
15. Prurigo Nodularis Report Methodology
16. DelveInsight Capabilities
17. Disclaimer
18. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
info@delveinsight.com
+919650213330
SOURCE DelveInsight